David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 23.09% |
| 2 | Technology | 17.04% |
| 3 | Healthcare | 13.44% |
| 4 | Consumer Discretionary | 13.38% |
| 5 | Financials | 7.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VSLR
2076
DELISTED
VIVINT SOLAR, INC.
VSLR
| $2.15M | ﹤0.01% |
432,000
-54,325
| -11% | -$250K |
|
|
BFYT
2077
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
| $2.15M | ﹤0.01% |
+80,005
| New | +$2.83M |
|
2078
CALL
Fortinet
FTNT
$123B
| $2.13M | ﹤0.01% |
127,000
| – | – |
|
2079
Chunghwa Telecom
CHT
$33.3B
| $2.13M | ﹤0.01% |
59,873
-18,778
| -24% | -$654K |
|
|
HABT
2080
DELISTED
The Habit Restaurants, Inc. - Class A
HABT
| $2.13M | ﹤0.01% |
196,558
-66,519
| -25% | -$732K |
|
|
BGG
2081
DELISTED
Briggs & Stratton Corp.
BGG
| $2.12M | ﹤0.01% |
179,132
-32,697
| -15% | -$425K |
|
|
GNC
2082
DELISTED
GNC Holdings, Inc.
GNC
| $2.12M | ﹤0.01% |
+776,749
| New | +$2.2M |
|
2083
Accenture
ACN
$116B
| $2.12M | ﹤0.01% |
12,032
-3,964
| -25% | -$623K |
|
2084
AngloGold Ashanti
AU
$59.8B
| $2.12M | ﹤0.01% |
161,708
-769,419
| -83% | -$10.3M |
|
2085
CALL
Conagra Brands
CAG
$7.71B
| $2.12M | ﹤0.01% |
+76,300
| New | +$1.75M |
|
2086
PUT
Howmet Aerospace
HWM
$106B
| $2.12M | ﹤0.01% |
+144,353
| New | +$2.07M |
|
2087
PUT
AGCO
AGCO
$7.74B
| $2.11M | ﹤0.01% |
30,300
| – | – |
|
|
THR
2088
DELISTED
Thermon Group Holdings
THR
| $2.1M | ﹤0.01% |
85,865
-52,677
| -38% | -$1.26M |
|
|
ABB
2089
PUT
DELISTED
ABB Ltd
ABB
| $2.1M | ﹤0.01% |
111,500
| – | – |
|
2090
McCormick & Company Non-Voting
MKC
$14.7B
| $2.1M | ﹤0.01% |
27,890
-226,902
| -89% | -$15.3M |
|
2091
PUT
Signet Jewelers
SIG
$3.18B
| $2.1M | ﹤0.01% |
77,200
+22,500
| +41% | +$621K |
|
|
GCI
2092
DELISTED
Gannett Co., Inc
GCI
| $2.1M | ﹤0.01% |
198,940
-192,662
| -49% | -$2.08M |
|
2093
Harmonic Inc
HLIT
$1.36B
| $2.09M | ﹤0.01% |
385,393
+9,027
| +2% | +$47.9K |
|
|
PTLA
2094
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $2.08M | ﹤0.01% |
60,000
| – | – |
|
|
KAMN
2095
DELISTED
Kaman Corp
KAMN
| $2.08M | ﹤0.01% |
35,605
-21,761
| -38% | -$1.28M |
|
|
RETA
2096
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $2.08M | ﹤0.01% |
24,329
+5,133
| +27% | +$426K |
|
2097
Collegium Pharmaceutical
COLL
$832M
| $2.07M | ﹤0.01% |
+137,017
| New | +$2.19M |
|
2098
Wipro
WIT
$17.8B
| $2.07M | ﹤0.01% |
1,041,848
-918,827
| -47% | -$1.87M |
|
2099
Agree Realty
ADC
$9.17B
| $2.06M | ﹤0.01% |
29,716
-145,123
| -83% | -$9.39M |
|
2100
CALL
Visteon
VC
$2.74B
| $2.06M | ﹤0.01% |
30,600
+8,600
| +39% | +$647K |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $2.66B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 23% of assets, down from 26% a quarter earlier, followed by Technology and Healthcare.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.